Tadalafil

證據等級: L5

預測適應症: 10 個

Tadalafil: From Pulmonary Arterial Hypertension to Kyphoscoliotic Heart Disease

One-Sentence Summary

Tadalafil is a PDE5 inhibitor internationally approved for erectile dysfunction, benign prostatic hyperplasia, and pulmonary arterial hypertension (PAH, marketed as Adcirca), but it currently holds no SAHPRA registration in South Africa. Of 10 TxGNN-predicted indications reviewed for this candidate, only Kyphoscoliotic Heart Disease shows a plausible mechanistic link to tadalafil’s known PAH indication — the other nine, including the highest-scoring signal, are flagged as likely model noise with no supporting mechanism. No clinical trials or published literature currently support tadalafil use specifically in kyphoscoliotic heart disease, placing this candidate at an early, hypothesis-generating stage.

Note on candidate selection: This evidence pack scored 10 candidate indications by raw TxGNN rank. Nine of them — including the top-ranked “Ambras type hypertrichosis universalis congenita” (score 99.98%) — were annotated by the source rationale as mechanistically implausible or contradicted by existing evidence (e.g., PDE5 inhibitors are known to trigger migraine-like headache as an adverse effect, not treat migraine). Only Kyphoscoliotic Heart Disease (rank 7, score 99.43%) carries a credible mechanistic rationale, so it is presented here as the lead candidate. The screened-out signals are summarized at the end of this report for transparency.

Quick Overview

Item	Content
Original Indication	Not registered in South Africa. Internationally approved for erectile dysfunction, BPH, and pulmonary arterial hypertension (PAH)
Predicted New Indication	Kyphoscoliotic Heart Disease
TxGNN Prediction Score	99.43%
Evidence Level	L4
South Africa Market Status	Not marketed
Number of SAHPRA Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data for this candidate has not been retrieved from DrugBank (data gap). Based on known information, tadalafil is a phosphodiesterase type 5 (PDE5) inhibitor that promotes vasodilation, particularly in pulmonary vasculature, and has an internationally approved indication for pulmonary arterial hypertension (Adcirca).

Kyphoscoliosis — spinal curvature affecting the thorax — can cause restrictive lung disease that progresses to secondary pulmonary hypertension and cor pulmonale (“kyphoscoliotic heart disease”). Because this downstream pathophysiology overlaps with the pulmonary hemodynamic abnormality that tadalafil is already approved to treat, there is an indirect mechanistic rationale for exploring tadalafil in this population.

However, this rationale is theoretical: it rests on overlap with an already-approved indication (PAH) rather than any tadalafil-specific study in kyphoscoliosis-associated heart disease. No trials or publications targeting this specific population currently exist.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

South Africa Market Information

Tadalafil is currently not registered with SAHPRA (market status: not marketed; 0 licenses on file). No South African product, dosage form, or approved indication text is available to summarize.

Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.

(Note: since tadalafil has no current SAHPRA registration, no local PI exists yet; the international Adcirca/Cialis PI can serve as an interim reference pending local registration.)

Other TxGNN Signals Screened Out (Not Pursued)

For transparency, the remaining 9 predicted indications in this evidence pack were reviewed and are not recommended for further evaluation:

Disease	Score	Reason for Hold
Ambras type hypertrichosis universalis congenita	99.98%	Rare chromosomal rearrangement disorder; no known mechanistic link to PDE5 inhibition
Hypertrichosis (disease)	99.98%	Speculative vasodilation-hair-growth analogy only; no evidence
Malformation syndrome (odontal/periodontal)	99.97%	Developmental anomaly; no plausible PDE5 mechanism
Syndrome with Dandy-Walker malformation	99.97%	Congenital posterior fossa malformation; no pharmacological relevance
Isolated genetic hair shaft abnormality	99.96%	Structural genetic defect; no mechanistic link
Familial isolated trichomegaly	99.65%	Associated with prostaglandin analogues, not PDE5 inhibitors
Migraine with brainstem aura	99.08%	PDE5-induced vasodilation is a known cause of headache, not a treatment
Migraine disorder	98.91%	Literature identified (PMID 17059442) documents tadalafil-induced migraine aura — evidence contradicts, not supports, this indication
Hypotrichosis simplex of the scalp	98.71%	Speculative scalp-perfusion analogy to minoxidil; no supporting data

These illustrate a known limitation of raw TxGNN ranking: high prediction scores do not guarantee mechanistic or clinical plausibility, and in the migraine case the literature signal actively runs counter to the therapeutic hypothesis.

Conclusion and Next Steps

Decision: Hold

Rationale: Tadalafil has no SAHPRA registration in South Africa, which blocks even a preliminary safety assessment (per data gap DG001). The lead candidate indication (kyphoscoliotic heart disease) is supported only by indirect mechanistic reasoning (L4) with no clinical trials or direct literature evidence, and the remaining nine TxGNN signals in this evidence pack are not clinically credible.

To proceed, the following is needed:

Detailed mechanism of action data from DrugBank (currently a data gap)
SAHPRA Professional Information / warnings and contraindications, or a regulatory pathway assessment for South African registration
Preclinical or proof-of-concept clinical evidence specifically in kyphoscoliosis-associated pulmonary hypertension/cor pulmonale
Re-screening of TxGNN output using mechanistic plausibility filters before further candidates from this “multi” batch are advanced
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.